C-Rad AB (publ)

Established in 2004 and based in Uppsala, Sweden, C-Rad AB (publ) is a global innovator specializing in the development, manufacturing, and distribution of advanced systems designed for radiation therapy in cancer treatment. The company operates through its two core segments: Positioning and Imaging. Its extensive product portfolio features cutting-edge solutions such as Sentinel 4D CT, a laser-based optical surface scanning system. A significant portion of its offerings falls under the Catalyst family of surface image guided radiation therapy (SIGRT) solutions, including the foundational Catalyst 4D system; Catalyst HD, which enables online patient tracking both before and during stereotactic radiation therapy; Catalyst+ for high-precision patient positioning, managing intra-fraction motion, and respiratory gating; and Catalyst+ HD, which delivers these same capabilities for both conventional and stereotactic treatment methods. Further specialized products encompass Catalyst Tomo for enhanced positioning in tomotherapy and Catalyst PT for real-time tracking during particle therapy. Additionally, C-Rad provides Cyrpa laser positioning devices, cAccessory for automating the registration and validation of treatment accessories, and cPatient for contactless, automated patient identity verification. Beyond its products, the company offers crucial services, including installation, application training, and comprehensive after-sales support.

C-Rad AB (publ) trades as CRAD-B.ST on STO. The company is classified in Healthcare / Medical - Devices and reports in SEK.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

C-Rad AB (publ) can be compared against peers such as ADDvise Group AB (publ), BICO Group AB (publ), I-Tech AB, Oncopeptides AB (publ), OssDsign AB (publ), Sedana Medical AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.13B, beta of 0.72, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CRAD-B.ST currently shows total debt of N/A and beta of 0.72. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.c-rad.se

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.